NIH Guide: Weekly Index for October 16, 2020

Funding Opportunities

• Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional)
  (PA-20-272)
  National Institutes of Health
  National Institute on Alcohol Abuse and Alcoholism
  National Institute on Aging
  National Institute of Allergy and Infectious Diseases
  National Institute of Arthritis and Musculoskeletal and Skin Diseases
  National Institute of General Medical Sciences
  National Cancer Institute
  National Institute on Drug Abuse
  National Institute on Deafness and Other Communication Disorders
  National Institute of Dental and Craniofacial Research
  National Institute of Diabetes and Digestive and Kidney Diseases
  National Institute of Environmental Health Sciences
  National Eye Institute
  National Human Genome Research Institute
  National Heart, Lung, and Blood Institute
  National Library of Medicine
  National Institute of Mental Health
  National Institute of Nursing Research
  National Institute of Neurological Disorders and Stroke
  National Center for Advancing Translational Sciences
  John E. Fogarty International Center
  National Institute of Biomedical Imaging and Bioengineering
  Office of Research on Women's Health
  Office of Behavioral and Social Sciences Research
  National Institute on Minority Health and Health Disparities
  National Center for Advancing Translational Sciences
  Application Receipt Date(s): Due dates may vary by awarding IC. See the awarding ICs web site or applicable Notice of Special Interest (NOSI) for appropriate Application Due Dates. Applicants may also contact their respective awarding IC. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
• Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH2/UH3 Clinical Trial Not Allowed)
  (PAR-20-313)
  National Cancer Institute
  Application Receipt Date(s): February 18, 2021; July 9, 2021; October 8, 2021; February 14, 2022; July 11, 2022; October 11, 2022; February 14, 2023; July 10, 2023; October 10, 2023
• Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH3 Clinical Trials Not Allowed)
  (PAR-20-314)
  National Cancer Institute
  Application Receipt Date(s): February 18, 2021; July 9, 2021; October 8, 2021; February 14, 2022; July 11, 2022; October 11, 2022; February 14, 2023; July 10, 2023; October 10, 2023
• Discovery of Cell-based Chemical Probes for Novel Brain Targets (R21 Clinical Trial Not Allowed)
  (PAR-21-028)
  National Institute of Mental Health
  National Institute on Aging
  National Institute on Drug Abuse
  National Eye Institute
  Application Receipt Date(s): Standard dates apply. The first standard due date for this FOA is February 16, 2021.
• Discovery of in vivo Chemical Probes for the Nervous System (R01 Clinical Trial Not Allowed)
  (PAR-21-029)
  National Institute of Mental Health
  National Institute on Aging
  National Institute on Drug Abuse
  National Eye Institute
  Application Receipt Date(s): Standard dates apply. The first standard due date for this FOA is February 5, 2021.
• NINDS Ruth L. Kirschstein National Research Service Award (NRSA) for Training of Postdoctoral Fellows (F32 Clinical Trial Not Allowed)
  (PAR-21-032)
  National Institute of Neurological Disorders and Stroke
  Application Receipt Date(s): February 11, 2021, June 9, 2021, October 14, 2021, February 9, 2022, June 8, 2022, October 11, 2022, February 9, 2023, June 8, 2023, and October 10, 2023.
• NLM Grants for Scholarly Works in Biomedicine and Health (G13 Clinical Trial Not Allowed)
  (PAR-21-046)
  National Library of Medicine
  Application Receipt Date(s): February 26, 2021, February 24, 2022 and February 24, 2023.
• Integrative Neuroscience Initiative on Alcoholism (INIA) Consortia Administrative Resource Core (U24) (Clinical Trial Optional)
  (RFA-AA-20-011)
  National Institute on Alcohol Abuse and Alcoholism
  Application Receipt Date(s): May 26, 2021
• Integrative Neuroscience Initiative on Alcoholism (INIA) Consortia Research Resource (U24) (Clinical Trial Optional)
  (RFA-AA-20-012)
  National Institute on Alcohol Abuse and Alcoholism
  Application Receipt Date(s): May 26, 2021
• Integrative Neuroscience Initiative on Alcoholism (INIA) Consortia (U01 Clinical Trial Optional)
  (RFA-AA-20-013)
  National Institute on Alcohol Abuse and Alcoholism
  Application Receipt Date(s): May 26, 2021
• New Cohorts for Environmental Exposures and Cancer Risk (CEECR; UG3/UH3 Clinical Trial Not Allowed)
  (RFA-CA-20-049)
  National Cancer Institute
  National Institute of Environmental Health Sciences
  Application Receipt Date(s): January 29, 2021 No late application will be accepted for this Funding Opportunity Announcement.
• New Cohorts for Environmental Exposures and Cancer Risk (CEECR) Coordinating Center (U24 Clinical Trial Not Allowed)
  (RFA-CA-20-050)
  National Cancer Institute
  National Institute of Environmental Health Sciences
  Application Receipt Date(s): January 29, 2021 No late application will be accepted for this Funding Opportunity Announcement.
• Collaborative Approaches to Engineer Biology for Cancer Applications (U01 Clinical Trial Not Allowed)
  (RFA-CA-20-054)
  National Cancer Institute
  National Institute of Biomedical Imaging and Bioengineering
  Application Receipt Date(s): January 15, 2021 No late applications will be accepted for this Funding Opportunity Announcement.
• Elucidation of mechanisms underlying complex morbidities of SUD and other mental Illnesses in people living with HIV/AIDS (R01 Clinical Trial Optional)
  (RFA-DA-21-012)
  National Institute on Drug Abuse
  Application Receipt Date(s): Only accepting applications for the AIDS Application Due Date(s) listed below.
• Utilizing In Vitro Functional Genomics Advances for Gene-Environment (G x E) Discovery and Validation (R01 Clinical Trial Not Allowed)
  (RFA-ES-20-018)
  National Institute of Environmental Health Sciences
  National Cancer Institute
  National Human Genome Research Institute
  Application Receipt Date(s): February 1, 2021
• From Genomic Association to Causation: A Convergent Neuroscience Approach to Linking Levels of Analysis for Understanding Neuropsychiatric Disorders (U19 Clinical Trial Optional)
  (RFA-MH-21-165)
  National Institute of Mental Health
  Application Receipt Date(s): March 17, 2021 No late applications will be accepted for this Funding Opportunity Announcement. All applications are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date(s). Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date